These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10048654)

  • 41. Neurodevelopmental disorders following thimerosal-containing childhood immunizations: a follow-up analysis.
    Geier D; Geier MR
    Int J Toxicol; 2004; 23(6):369-76. PubMed ID: 15764492
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association.
    Andrews N; Miller E; Grant A; Stowe J; Osborne V; Taylor B
    Pediatrics; 2004 Sep; 114(3):584-91. PubMed ID: 15342825
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An evaluation of the effects of thimerosal on neurodevelopmental disorders reported following DTP and Hib vaccines in comparison to DTPH vaccine in the United States.
    Geier DA; Geier MR
    J Toxicol Environ Health A; 2006 Aug; 69(15):1481-95. PubMed ID: 16766480
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Iatrogenic exposure to mercury after hepatitis B vaccination in preterm infants.
    Stajich GV; Lopez GP; Harry SW; Sexson WR
    J Pediatr; 2000 May; 136(5):679-81. PubMed ID: 10802503
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Update on the National Vaccine Injury Compensation Program.
    Edlich RF; Olson DM; Olson BM; Greene JA; Gubler KD; Winters KL; Kelley AR; Britt LD; Long WB
    J Emerg Med; 2007 Aug; 33(2):199-211. PubMed ID: 17692778
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Cross-Sectional Study of the Association between Infant Hepatitis B Vaccine Exposure in Boys and the Risk of Adverse Effects as Measured by Receipt of Special Education Services.
    Geier DA; Kern JK; Homme KG; Geier MR
    Int J Environ Res Public Health; 2018 Jan; 15(1):. PubMed ID: 29329213
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism.
    Price CS; Thompson WW; Goodson B; Weintraub ES; Croen LA; Hinrichsen VL; Marcy M; Robertson A; Eriksen E; Lewis E; Bernal P; Shay D; Davis RL; DeStefano F
    Pediatrics; 2010 Oct; 126(4):656-64. PubMed ID: 20837594
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication.
    Geier MR; Geier DA
    Exp Biol Med (Maywood); 2003 Jun; 228(6):660-4. PubMed ID: 12773696
    [TBL] [Abstract][Full Text] [Related]  

  • 49. But what about mercury in vaccinations?
    Bateson T
    Br J Nurs; 2004 Sep 9-22; 13(16):955; author reply 955. PubMed ID: 15459995
    [No Abstract]   [Full Text] [Related]  

  • 50. Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United kingdom does not support a causal association.
    Heron J; Golding J;
    Pediatrics; 2004 Sep; 114(3):577-83. PubMed ID: 15342824
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Continuing increases in autism reported to California's developmental services system: mercury in retrograde.
    Schechter R; Grether JK
    Arch Gen Psychiatry; 2008 Jan; 65(1):19-24. PubMed ID: 18180424
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increases in thimerosol patch tests in Greece.
    Dórea JG; Rooney JP
    Pediatr Dermatol; 2011; 28(2):214. PubMed ID: 21504460
    [No Abstract]   [Full Text] [Related]  

  • 53. Thimerosal positivities: the role of organomercury alkyl compounds.
    Santucci B; Cannistraci C; Cristaudo A; Camera E; Picardo M
    Contact Dermatitis; 1998 Jun; 38(6):325-8. PubMed ID: 9687031
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of thimerosal recommendations on hospitals' neonatal hepatitis B vaccination policies.
    Brayden RM; Pearson KA; Jones JS; Renfrew BL; Berman S
    J Pediatr; 2001 May; 138(5):752-5. PubMed ID: 11343056
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Wells' syndrome following thiomersal-containing vaccinations.
    Koh KJ; Warren L; Moore L; James C; Thompson GN
    Australas J Dermatol; 2003 Aug; 44(3):199-202. PubMed ID: 12869046
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data.
    Madsen KM; Lauritsen MB; Pedersen CB; Thorsen P; Plesner AM; Andersen PH; Mortensen PB
    Pediatrics; 2003 Sep; 112(3 Pt 1):604-6. PubMed ID: 12949291
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thiomersal sensitivity in health care workers.
    Rees S; Gibson J; Forsyth A; Wray D
    Br Dent J; 1997 Dec 13-27; 183(11-12):395. PubMed ID: 9447766
    [No Abstract]   [Full Text] [Related]  

  • 58. What happened to primum non nocere?
    Seal JB; Daum RS
    Pediatrics; 2001 May; 107(5):1177-8. PubMed ID: 11331704
    [No Abstract]   [Full Text] [Related]  

  • 59. Sensitization to thimerosal (Merthiolate) is still present today.
    van 't Veen AJ; van Joost T
    Contact Dermatitis; 1994 Nov; 31(5):293-8. PubMed ID: 7867326
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thimerosal exposure and disturbance of emotions specific to childhood and adolescence: A case-control study in the Vaccine Safety Datalink (VSD) database.
    Geier DA; Kern JK; Homme KG; Geier MR
    Brain Inj; 2017; 31(2):272-278. PubMed ID: 28102704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.